Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Free Cash Flow (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Free Cash Flow for 16 consecutive years, with $74.6 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 390.18% to $74.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $127.0 million through Dec 2025, up 22.83% year-over-year, with the annual reading at $127.0 million for FY2025, 22.83% up from the prior year.
  • Free Cash Flow hit $74.6 million in Q4 2025 for Ironwood Pharmaceuticals, up from $47.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $80.2 million in Q1 2023 to a low of -$15.1 million in Q2 2025.
  • Historically, Free Cash Flow has averaged $47.4 million across 5 years, with a median of $48.1 million in 2021.
  • Biggest YoY gain for Free Cash Flow was 390.18% in 2025; the steepest drop was 145.11% in 2025.
  • Year by year, Free Cash Flow stood at $64.4 million in 2021, then increased by 22.92% to $79.2 million in 2022, then tumbled by 55.03% to $35.6 million in 2023, then crashed by 57.29% to $15.2 million in 2024, then surged by 390.18% to $74.6 million in 2025.
  • Business Quant data shows Free Cash Flow for IRWD at $74.6 million in Q4 2025, $47.6 million in Q3 2025, and -$15.1 million in Q2 2025.